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Abstract
The number of humanized mouse models for the human immunodeficiency virus (HIV)/acquired immunode-
ficiency syndrome (AIDS) and other infectious diseases has expanded rapidly over the past 8 years. Highly
immunodeficient mouse strains, such as NOD/SCID/gamma chainnull (NSG, NOG), support better human
hematopoietic cell engraftment. Another improvement is the derivation of highly immunodeficient mice,
transgenic with human leukocyte antigens (HLAs) and cytokines that supported development of HLA-restricted
human T cells and heightened human myeloid cell engraftment. Humanized mice are also used to study the HIV
reservoir using new imaging techniques. Despite these advances, there are still limitations in HIV immune
responses and deficits in lymphoid structures in these models in addition to xenogeneic graft-versus-host
responses. To understand and disseminate the improvements and limitations of humanized mouse models to the
scientific community, the NIH sponsored and convened a meeting on April 15, 2015 to discuss the state of
knowledge concerning these questions and best practices for selecting a humanized mouse model for a par-
ticular scientific investigation. This report summarizes the findings of the NIH meeting.
Introduction
The plenary lecture, entitled ‘‘Of Next GenerationHumanized Mice and Men,’’ was presented by Dr. Leo-
nard D. Shultz. Preclinical testing in humanized mice has been
employed for studies of human immunodeficiency virus-1
(HIV-1) pathogenesis and latency, drug therapy, vaccine de-
velopment, gene therapy, and mucosal immunity in preparation
for clinical trials.1 Infectious agents that have been investigated
in humanized mice so far include HIV, human T lymphotropic
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virus 1, influenza, Rift Valley fever, dengue virus, Epstein Barr
virus, Ebola virus, cytomegalovirus (CMV), measles virus,
Salmonella typhi, Mycobacterium tuberculosis, Neisseria gon-
orrhea, and Plasmodium falciparum.2
The CB17 strain carrying the spontaneous severe com-
bined immunodeficiency (Prkdcscid, abbreviated as scid)
mouse mutation was the first model in the chronological
development path of humanized mouse models, followed by
the NOD/Lt-scid mouse and the highly immunodeficient
NOD.Cg-PrkdcscidIl2rgtm1Wjl/Sz (NSG) mouse.3–6 The NOD/
Lt background confers defects in innate immunity, im-
paired macrophage activation, lack of hemolytic com-
plement, and human-like polymorphism in the signal
regulatory protein alpha (Sirpa) gene. The scid mutation
prevents development of mature T and B cells. The in-
terleukin 2 (IL-2) receptor common gamma chain-
targeted mutation (IL2rgnull) inhibits the expression of
receptors for IL-2, -4, -7, -9, -15, and -21 and prevents
natural killer (NK) cell development.
Described hereunder are the hematolymphoid engraftment
methods for various humanized mouse models (see also
Table 1):
Human peripheral blood lymphocytes-SCID (Hu-PBL-
SCID): Human peripheral blood leukocytes are injected
intraperitoneally (IP) or intravenously (IV) into an immu-
nodeficient mouse. This procedure leads to efficient T-cell
engraftment, but the mice develop lethal xenogeneic graft-
versus-host disease (GvHD).
Hu-SRC-SCID (SRC = ‘‘scid repopulating cell’’): Human
hematopoietic stem cells (HSCs) from bone marrow, um-
bilical cord blood, mobilized peripheral blood, or fetal liver
are injected IV into sublethally irradiated neonatal or adult
immunodeficient mice. This leads to the development of
multiple hematopoietic lineages. The human T cells are ed-
ucated in the mouse thymus.
SCID-hu: Human fetal liver and thymus fragments are
transplanted under the kidney capsule of CB17-scid mice. A
functional human thymus develops; however, there is mini-
mal peripheral immune system development.
Bone marrow, liver, thymus (BLT) mouse: Human fetal
liver and thymus fragments are implanted under the
kidney capsule of sublethally irradiated NSG or NOD-
scid mice, and in addition autologous fetal HSCs are in-
jected IV. The results are robust development of multiple
hematopoietic lineages and T-cell education in the human
thymus. One disadvantage is the development of lethal
GvHD in some animals after more than 20 weeks of
engraftment.
Table 1. Major Strain Platforms for Humanized Mice
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The main limitations of current humanized mouse model
are as follows7:
1. Engraftment with mature human T cells leads to xe-
nogeneic GvHD.
2. Human leukocyte antigen (HLA) molecules are re-
quired for appropriate T-cell selection following hu-
man HSC engraftment.
3. Many human cytokines and other factors are species
specific.
4. Remaining innate immunity impairs engraftment.
5. Impaired humoral immune responses, low level of
immunoglobulin production, and impaired immuno-
globulin class switching.
6. Impaired lymph node development, poorly developed
germinal centers.
Next generation humanized mice
Mouse major histocompatibility complex (MHC) class I
(NSG-B2mtm1Unc) and (H2D1tm1Bpe H2K1tm1Bpe(KD)null or
class II (NSG-H2-Ab1tm1Gru) (abbreviated as I-Anull) and
H2dlAb1-Ea (abbreviated as I-A/I-E)null) knockout (KO) mice
have been developed to reduce xenogeneic GvHD. Progress has
also been made in generating a panel of human HLA class I and
II transgenic NSG mice. NSG class I transgenic mice available
include expression of HLA-A2, A11, A24, B7, B27, and Cw3
alleles, and NSG class II transgenic NSG mice available include
HLA-DR1, DR2, DR3, DR4, and DQ8 alleles. For example,
NSG-HLA-A2 transgenic mice engrafted with HLA-A2+ HSCs
develop HLA-A2-restricted human cytotoxic T cells.
Another new approach is the transgenic expression of
human cytokines in immunodeficient mouse strains and tar-
geting of mouse genes.8 The new NSG-KitW-41 mice support
human HSC engraftment without X-ray preconditioning.
NSG-Ifnar1tm1Agt [type I interferon (IFN) receptor KO] mice
show increased sensitivity to dengue virus infection and in-
creased sensitivity for testing neutralizing activity of anti-
dengue human IgM antibodies. Another emerging model
for humanized mice is the implantation of human-induced
pluripotent stem cells-derived thymic epithelial cells into
NSG-Foxn1nu (nude) mice.
Preexposure Prophylaxis and Novel Treatment
Strategies for HIV/Acquired
Immunodeficiency Syndrome
Dr. Ramesh Akkina’s presentation highlighted the util-
ity of humanized mice in multiple areas of HIV/acquired
immunodeficiency syndrome (AIDS) research in generating
important preclinical data. Hu-HSC mice derived by inject-
ing human CD34+ HSCs into neonatal C.129-Rag2tm1Fwa
Il2rgtm1Sug (Rag2-/-cc-/-) mice (Rag-hu mice) were primarily
used in these studies.9 Multilineage human hematopoiesis is
seen in these mice, which permits efficient HIV infection.
Long-term viremia lasting more than 1 year could be estab-
lished with both CXCR4- and CCR5-tropic viruses.9 With the
presence of HIV-susceptible cells in mucosal tissues, this
model also permits HIV transmission through both vaginal and
rectal routes; thus it is suitable for the evaluation of HIV
preexposure prophylactic (PrEP) strategies.9
The integrase inhibitor raltegravir (RAL) and CCR5 in-
hibitor maraviroc (MVC) were tested as oral PrEP in hu-
manized mice and were shown to protect 100% of the mice
from intravaginal challenge.10 In the context of topical mi-
crobicide application, protection was also achieved with
MVC and a broadly neutralizing antibody (bNAb) VRC01
against vaginal HIV-1 challenge.11,12 A major question for
PrEP is the optimal concentration of combination anti-
retroviral therapy (cART) (which is designed for therapeutic
purposes) that needs to be reached in mucosal tissues for
conferring full protection against viral exposure. In this con-
text, the hu-mice were found to be suitable for conducting
pharmacokinetics-pharmacodynamics (PK-PD) studies.13
ART drugs tenofovir (TFV), MVC, and RAL both individually
and in combination (TFV+RAL, TFV+MVC, RAL+MVC)
were tested. Higher concentrations were found in mucosal
tissues than in plasma, and the drug interactions and syner-
gistic effects are currently being evaluated.
In the second part of the talk, anti-HIV small interfer-
ing RNAs (siRNAs) were shown to be highly effective in
suppressing viral replication in vitro, but specific delivery to
HIV-infected cells in vivo has been difficult. To overcome
this hurdle, siRNAs conjugated with an HIV-1 gp120-
specific aptamer were tested in HIV-infected hu-mice.14
Marked suppression of viral loads was seen with concomitant
protection against viral-mediated CD4 T-cell loss.
The third part of the talk focused on potentiating antiviral
immune responses through PD-1 blockade.15 Mice treated
with human anti-PD-L1 monoclonal antibody (mAb) showed
decreased viral loads and improved T-cell function, sug-
gesting its potential application for immuno-enhancement
therapy. The advantages of the Hu-HSC model over BLT
mice for some studies are summarized as follows9:
 Easy to prepare and lower cost
 More animals can be generated per cohort
 Negligible GvHD and longer life span
 Chronic HIV infection lasting more than 1 year
 Long-term safety and toxicity assessments possible
Dr. Alejandro B. Balazs presented a novel approach for
delivery of bNAbs, called vectored immunoprophylaxis
(VIP). Adeno-associated virus (AAV; serotype 8) is used as a
vector, because it is nonpathogenic in humans, nonintegrat-
ing, and has excellent expression characteristics in vivo.
Despite the limited capacity to carry foreign genes (4.8 kb), a
transgene for the expression of antibody from muscle cells
was presented.16 In the first experiment, BLT mice were
administered a vector resulting in expression of 100 lg/ml of
VRC07G54W antibody and challenged intravaginally 21
times with the transmitted founder strain of HIV REJO.c. VIP
protected against CD4 T-cell loss in splenic lymphocytes, gut
intraepithelial lymphocytes (IEL), gut lamina propria lym-
phocytes (LPL), and vaginal LPL. All treated mice were
entirely resistant to mucosal challenge with the REJO.c
founder strain by sensitive viral load assays.17
The second experiment addressed vectored immunother-
apy for established HIV infections. BLT mice were infected
with REJO.c, given a suboptimal highly active antiretroviral
therapy (HAART) regimen, which transiently suppressed
viremia. These animals were administered AAV-expressing
VRC07 antibody. After the antibody concentration reached a
stable plateau, HAART was withdrawn. VRC07 in this model
resulted in durable suppression (7 weeks below 103 RNA
copies/ml) of REJO.c despite the lack of effective control of
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virus. Dr. Balazs described a third experiment, in which AAV
vectors expressing either PG9, PGT121, or VRC07 were
prophylactically administered, and the mice challenged with
107 human CD4 cells from an infected patient suppressed
with ART drugs. The blood was monitored for signs of virus
emerging from infected cells. High concentrations were
achieved for PGT121 (219 lg/ml) and PG9 (58 lg/ml) and
lower concentrations for VRC07 (1.6 lg/ml), but only
PGT121 protected the mice from HIV infection and CD4 cell
loss. In contrast to PG9 and VRC07, the PGT121-transfused
mice had undetectable viral load (below 103 RNA copies/ml),
but the PG9- and VRC01-treated animals became viremic to
similar levels as the control mice. In conclusion, VIP enables
the long-lived expression of any desired antibody after a
single intramuscular injection.
Dr. Fatah Kashanchi’s talk discussed the use of irradiation
to activate viral transcription and induce apoptosis in HIV-1-
infected cells. It has previously been shown that HIV-1 long
terminal repeat (LTR) can be induced with various transcrip-
tion activators including irradiation,18 which can be reversed
by specific peptide or cyclin-dependent kinase inhibitors in
humanized mouse models.19–22 Here, total body irradiation
was used to better define the latent tissue reservoirs in animals
and also potentially use low-level irradiation as part of a ‘‘kick
and kill’’ strategy activating HIV-1 cells under ART. Total
body irradiations are frequently used to treat lymphomas, in-
cluding solid epithelial tumors, lymphomas, breast, neck, and
head cancers, and Hodgkin and non-Hodgkin lymphomas.
Total body radiotherapy was also applied for the ‘‘Berlin’’
patient before CCR5D32/D32 transplantation.
Using an NSG ‘‘latent HIV mouse model’’ under a cocktail
of cART, Dr. Kashanchi’s laboratory was able to show that
latent viruses could be activated using low-level whole body
irradiation.23 These low doses were not lethal or cancerous to
animals at least up to 6 months. The question is whether T cells
are equally affected by low-level irradiation compared to
myeloid cells. It was shown that X-ray irradiation activates
HIV-1 transcription by removing negative inhibitors from
HIV-1 DNA and promotes transcriptional elongation. The
effect may be further enhanced by proteasome inhibitors (to
improve Tat stability in vivo). Latently infected T cells are
more sensitive to cell death (as compared with uninfected T
cells) by low-level irradiation than myeloid cells, possibly by
activation of the wild-type p53 pathway in cells. The effect of
cell death was not observed in myeloid-infected (or uninfect-
ed) cells with low-level irradiation, pointing to a different
mechanism of apoptosis in T cells versus myeloid cells. Im-
portantly, most tissues (blood, liver, lung, brain, and spleen)
from NSG-humanized mice contain latent HIV-1 that can be
activated with low-level irradiation alone. Reverse phase
protein microarray on few infected cells can show the status of
latently infected cells (i.e., senescence vs. exhaustion) in the
presence or absence of activators. Irradiation plus ALLN
(proteasome inhibitor) or bryostatin enhances transcription
activity more than low-level irradiation alone. Collectively,
the data indicate that latent HIV-1 can be transcriptionally
activated with low-level irradiation, which is not toxic to the
host, and potentially ‘‘purge’’ the virus from various secluded
reservoirs including brain.
Dr. Scott G. Kitchen reported on the characterization of
chronic immune activation and type I IFN signaling during
HIV infection in humanized mice. The progression from naive
to exhausted T cells involves chronic antigen stimulation
during chronic infection, triggering the expression of exhaus-
tion markers PD-1, LAG-3, CD244 (2B4), and Tim-3.24,25
Similar to what is observed in humans, HIV-infected BLT
mice have elevated expression of cellular activation and ex-
haustion markers. In particular, the expression of exhaustion
(PD-1, Tim-3) and activation markers (HLA-DR) is increased
in chronically infected BLT mice. T cells from infected mice
have higher Tim-3 expression and an impaired ability to pro-
duce IL-2 and IFN-c upon stimulation. After HIV infection of
humanized mice containing human cells genetically modified
with a molecularly cloned anti-HIV T-cell receptor (TCR),26
Tim-3+ HIV antigen-specific cells produce less IFN-c and IL-2
in response to immunodominant HIV Gag p17 (SL9) peptide
stimulation. It was also found that Tim-3 is elevated on HIV
nonspecific T cells in chronically infected mice.
Type I IFNs (IFNa and b) have both antiviral and immu-
nomodulatory effects and could contribute to chronic immune
activation and exhaustion.27 HIV-infected mice have chroni-
cally elevated levels of type I IFN signature gene expression
than uninfected animals. In addition, HIV infection upregu-
lates immunoregulatory dendritic cells,28 as characterized by
high levels of expression of both PD-L1 and CD95. Type I IFN
receptor blockade significantly reduced type I IFN signaling,
led to a reduction of activation and exhaustion markers on T
cells, and improved their cytokine production upon stimula-
tion. The BLT mouse model can be used to examine the
mechanisms of immune defects during HIV infection and for
testing therapies aimed at reversing immune suppression.
Dr. Florian Klein presented data from monocloncal an-
tibody therapy studies in HIV-1YU2-infected humanized
mice. NOD.129S7(B6)-Rag1tm1Mom/Sz (NRG) mice were
irradiated with 1.0–3.6 Gray (Gy) and 4–6 h later injected
intrahepatically with human HSCs. HIV-1-infected hu-mice
demonstrated stable HIV-1 infection for more than 100 days,
had a decreasing CD4+/CD8+ T-cell ratio, and the virus di-
versified within the host (2.2 · 10-3 mutations/bp 21 days
after infection).
Antibody-mediated therapy with a single bNAb (e.g., 45–
46G54W) led to a transient decrease viremia, but escape oc-
curred rapidly mediated by HIV envelope mutations (e.g.,
N279H and N280Y for antibody 45–46G54W).29 In contrast,
antibody combinations (e.g., 3BNC117 + 10-1074+PG16)
led to a sustained decrease of HIV-1 RNA.29,30
In contrast to the experiments in hu-mice, monotherapy
appeared to be more effective in nonhuman primates: A
single infusion with 3BNC117 or 10-1074 resulted in a
transient suppression and although classical escape mutations
were detected after 10-1074 monotherapy (N332K, S334N),
no apparent escape was seen after 3BNC117 infusion.31 In
conclusion, antibody monotherapy can transiently suppress
viremia in HIV-1-infected hu-mice, but escape and rebound
occur rapidly. However, escape can be prevented by com-
bining bNAbs that target different epitopes. Single bNAbs
can effectively decrease viremia in nonhuman primates and
in some cases maintain suppression until antibody serum
levels decay.31,32
In a recent clinical trial, 30 mg/kg of 3BNC11733 was
given as a single infusion to uninfected or HIV-1-infected
individuals.34 The antibody was well tolerated and had
preferable pharmacokinetics. Interestingly, the average drop
in viremia at nadir was 1.48 log10 and a significant reduction
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of the viral load was detected up to 28 days after antibody
infusion.34
Finally, experiments in humanized mice demonstrated that
bNAbs can synergize with non- or weakly neutralizing an-
tibodies by inducing HIV escape variants. As shown in vitro,
escape variants can be more susceptible to commonly gen-
erated HIV antibodies (e.g., V3-loop antibodies). When the
bNAb 10-1074 was injected with one of the V3-loop anti-
bodies 10-188 or 1-79 into HIV-1YU2-infected humanized
mice, viremia was suppressed more effectively.35 Therefore,
HIV-1 infection is, in part, more readily controlled during
immunotherapy because escape from bNAbs can create holes
in the glycan shield that render the virus susceptible to oth-
erwise ineffective antibodies that are present in nearly all
HIV-infected individuals.
Dr. Jerome A. Zack presented modeling of cell-based
therapeutics in BLT mice. His laboratory has found that
anti-MART-1 HLA class I-restricted TCR (F5) introduced
into human stem cells results in the generation of mature
CD8 T cells, which can eliminate human melanomas in BLT
mice.36,37 In addition, an anti-HIV Gag class I-restricted
TCR introduced into human stem cells results in the gen-
eration of mature CD8 T cells that can greatly reduce HIV
replication in BLT mice.26,38 However, HLA restriction
renders TCR-based approaches difficult to use clinically
because multiple anti-HIV TCRs would be required. In
addition, rapid resistance of HIV would be likely because of
the rapid mutation rate.
A previously established approach created a CD4-zeta
chimeric antigen receptor (CAR), which contained the ex-
tracellular and transmembrane domains of the human CD4
molecule, and the CD3-zeta signaling domain. The CAR
recognizes HIVgp120 independent of HLA restriction. Li-
gation induces TCR signaling and activation. This construct
demonstrated stable, safe engraftment with a persistence of
greater than 10 years and has been used in peripheral T cells
in multiple clinical trials.39 It has modest clinical efficacy
because of functional defects in modified peripheral T cells.
The new CD4-zeta CAR Triple Vector expresses a
CCR5sh1005 gene for CCR5 knock down, a sh516 gene,
which targets the LTR R region of HIV-1 and a CD4-zeta
gene.40 NSG mice were implanted with the thy-liv ‘‘orga-
noid,’’ irradiated with 270 cGy, and CD34+ cells transduced
either with a control vector or with the Triple CD4CAR
vector, and then infected with HIV. CD4-zeta CAR-modified
stem cells develop into multiple hematopoietic lineages, such
as T cells, macrophages, and NK cells. CD4 CAR-expressing
cells have decreased expression of CD3, TCRab, and TCR
excision circles in thymocytes,40 suggesting that the CAR
leads to allelic exclusion of endogenous TCRs in some cells.
CAR-expressing T cells developed into effector cells and
were activated in response to HIV. CD4-zeta CAR-modified
mice have reduced HIV viral loads and preserved CD4+
T-cell counts than control mice. Engineered immunity is
potentially a feasible approach in eliminating chronic viral
infections.
Finally, human CD34+ cells can be engineered with TCRs
plus a nonimmunogenic positron emission tomography (PET)
reporter gene through lentiviral vectoring. Addition of the
proper PET tracer allows localization of antigen-specific cells
in vivo in BLT mice.41 This approach may be useful in tracking
engineered immune cells during clinical trials.
Mouse Viral Outgrowth Assay
Dr. Joel N. Blankson reported that NSG mice have a high
level of human T-cell engraftment and a high degree of im-
mune activation because of GvHD. For the mouse viral
outgrowth assay (MVOA), 25–55 million peripheral blood
mononuclear cells (PBMCs) from patients on suppressive
cART regimens (1–6 years) were IP injected into NSG mice.
Seven days later, anti-CD8 mAb was administered. The mice
were bled weekly to evaluate viral load and CD4 T-cell
count. All mice became viremic after PBMC transfer from
patients on suppressive cART regimens.42
Next, elite suppressors were studied to answer the question
whether MVOA is more sensitive than the quantitative viral
outgrowth assay (QVOA). Elite suppressors have much
lower frequencies of latently infected cells than patients on
cART.43 However, HIV isolates from HLA-B57 elite sup-
pressors replicate vigorously in BLT-humanized mice.44
Elite suppressors were selected who had a frequency of la-
tently infected cells ranging from 1 in 15 million to 1 in 25
million CD4+ T cells. Sixty-six million PBMCs from one
elite suppressor or 20–26 million purified CD4 T cells from
four other elite suppressors were injected IP into NSG mice.
On day 7 anti-CD8 mAb was administered IP to the mice
engrafted with PBMCs, and for the mice engrafted with pu-
rified CD4s, anti-CD8 mAb was given as needed. Two mice
were treated with anti-CD3 IP. The mice were bled weekly to
evaluate viral load and CD4 T-cell count. The NSG mice
became viremic after PBMC or CD4 transfer from elite
controllers. Elite suppressor CD8 T cells have potent antiviral
activity,45 and the expansion of these cells may potentially
explain why virus does not continue to replicate in vivo.
The advantages of the MVOA are as follows:
 Recapitulates what happens in vivo when cART is in-
terrupted.
 Continuous stimulation of cells for up to 6 weeks be-
cause of xenogeneic response.
 Can assay very large number of cells.
 Can be used for nonhuman primate (simian immuno-
deficiency virus) and human (HIV) studies.
 At least as sensitive as the QVOA; sensitivity may
increase with anti-CD3 and/or anti-CD28 mAbs treat-
ment in vivo.
Future directions are to validate the sensitivity with a lar-
ger number of patients to optimize in vivo stimulation with
mAbs, to determine whether low-level viremia represents
replication-competent virus, and to determine whether NSG
mice can be engrafted with CD4+ T cells from lymphoid
tissue [gut-associated lymphoid tissue (GALT), lymph
nodes].
Novel Mouse Models
Dr. Kim J. Hasenkrug presented the TKO-BLT model
(B6.129S-Rag2tm1FwaCd47tm1Fpl Il2rgtm1Wjl/J) (TKOs).46,47
CD47 is the ‘‘don’t eat me’’ signal, and ‘‘TKO’’ means triple
knock out. The animals develop T cells, B cells, NK cells,
dendritic cells, and other myeloid lineages, but no red blood
cells and platelets. Mouse splenocytes were transfused 5 days
post-transplantation to prevent radiation-induced anemia.
The TKO-BLT model has human lymphoid reconstitution in
the gut, such that the GALT reconstitution supports mucosal
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HIV infection with pathogenic loss of CD4+ T cells. HLA
class II-expressing cells and both CD4+ and CD8+ human
cells are present in lymphoid tissues. Spleens and mesenteric
lymph nodes form B-cell follicles with interspersed T cells.
TKO-BLT mice have functional immune systems. HIV-
specific IFNc Enzyme-Linked ImmunoSpot responses from
splenocytes could be detected 7 weeks postinfection (p.i.) and
could be mapped to different Gag, Pol, and Env peptides.
Antibodies (IgG) to gp120JR-CSF were present 8 weeks
p.i. although at levels lower than that seen in HIV-infected
patients. In vaccine experiments, no antibody responses were
detectable after inoculation of Ad5 HIV vaccine vectors or
DTP (diphtheria, tetanus, pertussis) vaccination. Experi-
ments to improve B-cell responses by transfusing mesen-
chymal stem cells isolated from human fetal lung to provide
human stromal cells in lymphoid tissues showed trafficking
to multiple tissues. However, there was no improvement
to vaccine-induced antibody responses. As seen with other
models, there is an age-dependent loss of B cells with a
concomitant increase in T cells and stable monocytes and
dendritic cells.
Evidence of possible GvHD was seen in only 2 of 55 co-
horts (more than 2,000 mice). Humanized mice in the TKO
background are healthy for more than 35 weeks with no signs
of GvHD. Thus, this model is an excellent platform for long-
term studies, such as HIV latency and cure.
Dr. Sofia Casares discussed the generation of NOD-
Rag1tm1Mom Il2rgtm1Wjl Tg(HLA-DRA,HLA-DRB1*0401)
39-2Kito/ScasJ (DRAG) mice.48 HLA-DR4 Tg RagKO
(C57BL/6) mice were crossed with NOD-Rag1tm1Mom
(RagKO mice). The hybrid mouse was backcrossed into the
NOD background for 12 generations. The resulting HLA
DR4 Tg Rag1 KO mouse was crossed with the NRG mouse,
resulting in the DRAG mouse. Compared with NRG mice,
DRAG mice express human HLA-DR4 molecules in cells
from spleen, thymus, and bone marrow. For humanization,
the DRAG mice were irradiated with 3.5 Gy and then infused
with human HSCs from umbilical cord blood that was en-
riched for CD34+ cells. The expression of HLA-DR4 mole-
cules favors engraftment of human pro-T cells in the mouse
thymus. The rate of human T-cell reconstitution is much
higher in the DRAG mice than in the NRG mice at 25 weeks
post-transfusion. In addition, all four human IgG subclasses
(1–4), human IgA, and human IgE can be found in a number
of the DRAG mice. The DRAG mice also elicit specific IgG
antibodies upon immunization with tetanus toxoid vaccine.
In addition, antibody responses to malaria parasites were
found (IgM and IgG).
DRAG mice can also be used as a resource to generate
mAbs. The DRAG mice are vaccinated with a protein, toxin,
or infectious agent. Upon euthanasia of the DRAG mice,
human B cells are recovered from the spleen, and B cell
hybridomas generated producing human mAbs. For example,
the 8F1-2C9 human IgG2 antibody inhibits malaria parasite
growth in vitro and oocyst development on Anopheles ste-
phensi mosquitos.49
Another new transgenic-humanized mouse is the DRAGA
mouse (NOD.HLA-A2.HLA-DR4.RagKO.IL2RgcKO). The
DRAGA mice are generated by crossing HLA-DR4
Tg/RagKO.IL2RgcKO (DRAG) mice with HLA-A2 trans-
genic mice. The resulting F1 generation is intercrossed,
and the F2 generation is selected for the HLA-A2.HLA-
DR4.RagKO.IL2RgcKO phenotype. DRAG and DRAGA
mice reconstitute similar number of human CD4 and CD8
cells. Human CD8 T cells from DRAGA mice are HLA-A2
restricted and functional, as shown by MHC dextramer
staining. Immunization with radiation-attenuated sporozoites
or live sporozoites under chloroquine prophylaxis confers
>80% malaria protection in humans, which can be experi-
mentally reproduced in the DRAGA mouse model. There-
fore, DRAGA mice may be useful for testing malaria
vaccines.
Dr. Mangala Rao discussed the immune response in
mucosal tissues of humanized DRAG mice. Mucosal mem-
ory CD4 T cells are of effector memory phenotype and en-
riched for CCR5 expression.50–52 Human cells reconstitute
the female reproductive tract (FRT) of humanized DRAG
mice. There is a distinct distribution of B and T cells in the gut
of humanized DRAG mice. CD4+ and CD4+CD8+ T cells are
highly enriched for CCR5 and a4b7 expression.
Concentrated stocks of primary HIV-1 were prepared for
mouse inoculation by ultracentrifugation and removal of
microsomes and exosomes by antiacetylcholinesterase beads
and anti-CD45 beads. The stocks were titrated on P4R5
HeLa-CD4-LTR-b-gal (MAGI) cells and had a TCID50 of
more than 105/ml. As little as 500 infectious units of primary
HIV-1 BaL were sufficient to infect a DRAG mouse in-
travaginally with HIV-1 BaL.
In conclusion, humanized DRAG mice show a high level
of reconstitution of human T and B cells in the gut, FRT, and
spleen. The majority of CD4+ T cells (79%–96%) exhibited a
memory phenotype. The majority of CD4+ T cells in the FRT,
IEL, LPL, and Peyer’s Patches (PP) expressed CCR5 (50%–
80%). Mucosal tissues, which are the primary sites of HIV-1
transmission, had CD4+a4b7+ T cells in varying frequencies.
The proportion of a4b7+ CD4+CD8+ T cells in IEL and LPL
was higher than that of a4b7+ CD4+ T cells. Finally, a single
low-dose intravaginal challenge with primary HIV-1 BaL
resulted in 100% infectivity of humanized DRAG mice.
Future studies include (1) imaging humanized mice infected
with luciferase-expressing HIV-1 to determine the localiza-
tion of the virus in the different organs/tissues and (2) im-
munization studies with subtype C gp145 adsorbed to
AL(OH)3 gel and added to unilamellar liposomes containing
monophosphoryl lipid A.
Dr. Atef Allam discussed the distribution of follicular
helper T (TFH) cells in gut tissues PP, LPL, and IEL) and in
the FRT of humanized DRAG mice before and after HIV-1
infection.53 TFH cells (CXCR5
+PD-1++ CD4+ T cells) are
characterized by high expression of PD-1, CXCR5, ICOS, and
BCL-6. Another subset of CD4+ T cells found in gut tissues
and FRT express intermediate levels of PD-1 and are named
pre-TFH cells (CXCR5
+PD-1+ CD4+ T or pTFH
+ cells). Their
frequency was higher in mucosal tissues of the gut and FRT
than in the lymphoid tissues of humanized DRAG mice. A
high proportion of TFH cells in mucosal tissues express
CXCR3, and there is a strong correlation between the ex-
pression of CXCR3, PD-1, and CCR5 and permissiveness to
HIV-1 infection. Since the finding of TFH cells in the FRT of
humanized DRAG mice was unexpected, their presence was
also confirmed in endocervical and ectocervical tissues ob-
tained from routine hysterectomies; the majority of CXCR5+
PD-1++CD4+ T cells expressed BCL-6, confirming the pres-
ence of human TFH cells in the human FRT.
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In conclusion, TFH cells accumulate in the PP and FRT
during the chronic phase of HIV-1 infection. TFH cells are
present in the endo- and ectocervix of humans and in the FRT
of humanized DRAG mice and are highly permissive to HIV-
1 with impaired IL-21 production over the course of infec-
tion. Owing to the high frequency of TFH cells in gut and
FRT, DRAG mice are a suitable model for testing HIV-1
vaccines.
Latency and Viral Dynamics
Dr. Andrew D. Luster presented data about the cellular
and viral dynamics of intravaginal HIV-1 transmission
in humanized NOD-scid BLT (BLT-NS) and NSG BLT
(BLT-NSG).54,55 One week before intravaginal infection,
BLT mice were pretreated with progesterone, followed by an
atraumatic intravaginal application of 105 TCID50 HIV-1 JR-
CSF. The viral dissemination and cytokine/chemokine ex-
pression in the BLT mice were characterized as follows: at
day 2 p.i., local amplification occurred in the cervico-vaginal
tract; hCXCL9, hCXCL10, and hTNFa were expressed.
Between days 2 and 6 p.i., the virus spread to the draining and
nondraining lymph nodes. Between days 8 and 15 p.i.,
hCXCL9, hCXCL10, and hIFNb were expressed in the
draining lymph nodes. Between days 10 and 15 p.i., the virus
could be detected in the mesenteric lymph nodes, the gut, and
plasma. At day 15 p.i., 85 of 90 (95%) BLT-NS and BLT-
NSG mice from 13 different cohorts were clearly positive for
plasma HIV RNA. Lymphocytes and pDCs accumulated in
the cervicovaginal tissue following HIV infection. In con-
clusion, the paradigm described for SIV infection of ma-
caques appears to be mirrored during HIV infection of
humanized BLT mice.56
The next study investigated the various stages of GvHD.
The clinical phenotype is divided into grade I (conjunctivitis
and/or blepharitis only), grade II (thinning hair and/or alo-
pecia at their surgical incision sites), and grade III (general-
ized alopecia and/or dermatitis). The pathologic phenotype
involves the following tissues:
 Skin (grade I: minimum infiltrates in epithelium and/or
hair follicles, grade II: important inflammation with
thicker epithelium, but preserved hair follicles, grade
III: complete loss of hair follicles).
 Cervico-vaginal tract (infiltration of CD45+ and CD3+
cells).
 Large intestine (infiltrates in the epithelium and ab-
normal cell death).
The number of histological changes in skin and cervico-
vaginal tract correlated directly with the clinical severity and
grade (I to III) of GvHD. The number of CD45+ and CD3+
cells increased with the clinical grade of GvHD, and may
render humanized mice more susceptible to HIV infection.
Dr. J. Victor Garcia presented work to develop the BLT-
humanized mouse as a flexible platform for the study of HIV
latency and persistence.57,58 The first step was to establish an
efficient ART regimen that results in consistent reduction of
plasma viral RNA (vRNA) levels in BLT mice. After 50 days
of infection, BLT mice were administered a combination of
RAL, emtricitabine, and TFV that reduced viral loads to
below detection levels (*670 copies/ml).59 To determine
whether bona fide HIV latency had been established, a
QVOA was performed using resting CD4+ T cells isolated
from multiple pooled organs from suppressed BLT mice.
Using this assay, an average of eight infectious units per
million cells (IUPM) were found in this model.59 Like in
humans, HIV plasma viral load rebounded after analytical
treatment interruption. Further analysis of the number of
vRNA+ cells that occur during ART demonstrated a durable
reduction in the levels of HIV-infected cells after treatment in
all tissues analyzed, including thymic organoid, spleen,
lymph nodes, liver, and lungs. But these results also dem-
onstrated the presence of a significant number of vRNA+ cells
in the tissues of suppressed mice.
The presence of vRNA+ cells despite therapy represents a
significant problem for eradication studies. Therefore, an
immunotherapeutic approach for the destruction of the ‘‘ac-
tive’’ reservoir of HIV-infected cells was evaluated. The
3B3-PE38 immunotoxin consisting of the Pseudomonas
aeruginosa exotoxin A translocation and cytotoxic domains
linked to an Env-targeting moiety was tested in vivo for its
ability to kill HIV-infected cells expressing vRNA that re-
main despite ART.60 The results demonstrated effective
in vivo killing of residual HIV+ cells in tissues of BLT-
humanized mice. Based on these results, the BLT mouse
model was presented as providing an experimental platform
for in vivo evaluation of ‘‘Kick and Kill’’ HIV eradication
strategies. Dr. Garcia also presented data regarding another
humanized animal model developed in his laboratory, the T-
cell only mouse (ToM).61 ToM mice are similar to BLT mice,
but they only receive the Thy-Liv implant and not the CD34+
HSC transplant. In this model, his laboratory demonstrated
the efficient establishment of HIV latency and reactivation
that occurs in the complete absence of human monocytes,
macrophages, and dendritic cells. Progress was also men-
tioned in the development of another model reconstituted
with human B cells and myeloid cells referred to as myeloid-
only mice, because these are the only HIV targets in this
model.
Gene Therapy
Dr. Priti Kumar gave an overview of the current ap-
proaches and clinical trials for HIV gene therapy. One ap-
proach to target human T cells and monocytes is through
CD7, which is a 40 kDa cell surface glycoprotein from the
immunoglobulin superfamily. It is expressed on the majority
of human thymocytes and peripheral blood T cells. A key
characteristic of CD7 is its rapid internalization after anti-
body binding, even with monovalent antibody fragments. A
humanized single chain antibody (scFv) targeting human
CD7 may be used for functional delivery of siRNA when
attached to a cell-penetrating peptide 9R. scFVCD7 targets
siRNA to naive/resting human T cells in Hu-HSC mice.
Treatment with a combination of siRNAs targeting viral gene
products and the CCR5 coreceptor prevents HIV infection in
Hu-HSC mice. scFvCD7-9R:siRNA treatment prevents viral
rebound in patient PBL-derived NSG mice. As shown by
microscopy, human T cells in the FRT of Hu-BLT mice can
also be specifically targeted with scFvCD7-9R:siRNA com-
plexes. The resulting CCR5 knockdown confers protection
against multiple exposures to the founder virus Rejo-1. A
more permanent gene therapy approach can be established
using lentiviral vectors pseudotyped with a modified Sindbis
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virus envelope protein (SIN), in which the IgG-binding do-
main of protein A (ZZ) was inserted into the E2 region for
binding to CD7. Human T cells of Hu-PBL mice are selec-
tively transduced with the ZZ-SIN:aCD7 construct. Mice
treated with the ZZ-SIN:aCD7 construct in combination
with shCCR5 resist HIV challenge and selectively expand
shCCR5-transduced cells.
An alternative gene-editing approach for mutating the
CCR5 gene uses triplex-forming peptide nucleic acids
(PNAs) that stimulate site-specific genome modification by
forming triplex structures that induce cellular pathways of
nucleotide excision repair and homology-dependent recom-
bination. Importantly, PNAs are very safe as they are not
themselves associated with nuclease activity and display
highly specific binding that does not tolerate even a 2 bp
mismatch obliterating off-target activity. PNAs can stimulate
the recombination of short 50–60 bp donor DNA fragments
for containing a stop codon into the human CCR5 gene.
PLGA nanoparticles have been created for codelivery of
PNA and donor DNA. These nanoparticles, upon injection
through the tail vein, can render hematopoietic cells HIV
resistant. HIV-1 can, therefore, be controlled in Hu-PBL
mice by PNA-mediated gene editing. Furthermore, PNA-
edited CD34+ HSCs from Hu-HSC mice can be transplanted
into secondary recipient mice to confer HIV resistance.
Dr. John C. Burnett presented combinatorial anti-HIV
RNA-based therapeutics in the NSG-humanized mouse
model. Two-day-old pups were irradiated with 100cGy and
intrahepatically injected with 5 · 105 CD34+ HSC from fetal
liver tissues. The distribution of CD45 cells was 33% human
origin and 67% mouse origin. Of the human CD45 cells, 38%
were hCD19, 17% hCD14, 29% hCD4, 9% hCD8, and 34%
hCD3 (more information on engraftment data is included
in62,63). Hu-NSG mice have central memory CD4+ T cells
(CD27, CD45RO) that are known to support latent infection.
Three groups of humanized mice were challenged with HIV-1
BaL or NL4-3 together with a control group. The highest
plasma viremia was detected after 2 weeks with a challenge
dose of 200 ng BaL p24, followed by 100 ng BaL p24, and
then 200 ng NL4-3 p24. The infected mice were placed on an
ART regimen of 300 mg TFV disoproxil fumarate, 200 mg
Emtricitabine, and 400 mg RAL in drinking water mixed with
MediDrop Sucralose. HIV RNA levels were reduced nearly
100-fold after 2 weeks of ART and were undetectable after 5
weeks, as measured by qRT-PCR. ARV-treated animals also
exhibited concurrent increases in the percentage of CD4+ T
cells in peripheral blood.
Next, he gave an overview of anti-HIV RNA-based ther-
apeutics. He evaluated a combinatorial RNA-based gene
therapy for HIV using lentiviral vector delivery with anti-
HIV siRNAs to silence CCR5 in an attempt to create an HIV-
resistant immune system.64
Specifically, the four constructs delivered individually were
a combination of small RNAs targeting tat, rev, CCR5, and a
conserved U5 region within the HIV-1 LTR and transactiva-
tion response element decoys in an MCM7 (DNA replication
licensing factor) platform. After HIV-1 JRFL challenge, the
combinatorial lentivectors suppressed viral replication and
protected CD4+ T lymphocytes and CD4+ monocytes.64
The next part of the talk focused on aptamers, which are
in vitro evolved nucleic acids that bind to selected ligands
(proteins, carbohydrates, and other nucleic acids) with high
affinities similar to antibodies. They are composed of single-
stranded DNA or RNA molecules, often with chemically
modified nucleotides. The discovery process involves the
selection of high-affinity binding aptamers out of as many as
1014 molecules from random sequence libraries. Six novel
CCR5 aptamer candidates were selected after eight rounds of
whole cell-based systematic evolution of ligands by expo-
nential enrichment. Aptamers can be used for targeted de-
livery of anti-HIV siRNAs (HIV gp120 envelope, CD4, CD7,
CCR5). An ex vivo HIV-1 challenge to test a CCR5-specific
aptamer (G-3) in humanized mouse spleen cells was per-
formed.65
Brain Models
The first neuroAIDS mouse model was developed by Drs.
William Tyor, Howard E. Gendelman, and Yuri Persidsky,
who transplanted infected human macrophages into the SCID
mouse brain to induce HIV encephalitis.66,67 When NOD/
SCID mice became available, HIV-infected macrophages
were injected intracranially and simultaneously Hu-PBL IP.
The model was useful for 2–4-week-long experiments.68
Later, central nervous system involvement was studied in the
CD34+ HSC-reconstituted NOD/scid-IL-2rcnull (CD34-NSG
model) during natural HIV-1 progression of disease.69 The
CD34-NSG model became a valuable tool for long-acting
antiretroviral drug(s) development (nanomedicine program
led by Dr. Gendelman).70,71
Another investigator at the University of Nebraska Medi-
cal Center, Dr. Mike Boska, conducted magnetic resonance
imaging (MRI), proton magnetic resonance spectroscopy,
and microstructural diffusion tensor MRI evaluations of the
humanized mouse brain. These models also provided the
possibility to observe longitudinal behavior, brain imaging,
and metabolite changes.72 The manganese (Mn)-enhanced
MRI strategy to see changes in neuronal activities by Mn2+
uptake was also tested on HIV-1-infected CD34-NSG
mice.73
Only a small number of human cells can be found in
perivascular spaces and meninges in humanized NSG mice.
Moreover, the cells very rarely show microglial morphology.
With HIV infection, trafficking of human cells in the brain
significantly increased; some cells had activated microglia
morphology and were HIV-1 p24 positive. Alternatively,
transplantation of dissociated fetal brain cell cultures led to
the inclusion of human cells with human microglia and
macrophages in NSG mice.74 Neurospheres prepared from a
human brain can be dissociated to single-cell suspension and
transplanted intracranially, whereas HSCs are transplanted
intrahepatically. Changes of supplemental growth factors
in vitro favored development of human astrocytes in vivo.
Simultaneous transplantation of CD34+ HSCs and human
astrocyte progenitor cells into newborn NSG mice is feasible.
The development of the humanized blood and brain (named
as ‘‘huBB’’ or ‘‘2B’’) in mice will be important for neu-
roAIDS studies. The amount of human astrocytes in selected
brain regions can reach 60%–90%, for example, in periven-
tricular spaces or the corpus callosum. Some animals were
able to establish a rostral migratory stream. These huBB mice
had usual levels of peripheral human cell engraftment and
HIV-1 infection. Mice engrafted with human neuroglial cells
can be used for studying immune responses, peripheral and
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brain pathology of HIV-associated opportunistic infections,
like JC virus, CMV, and other human-specific members of
the Herpesviridae family.
The University of Nebraska Medical Center was awarded
a Center for Humanized Mice grant (R24 OD 018546).
The Center is creating five new mouse strains with improved
background for human immune system function (NSG-
Cmah-/-), human macrophages distribution (CD11b- and
CD11c-DRT-NSG, CD18mt-NSG, i.e., Joker), and human-
type liver metabolism (PXR-CAR-CYP3A4/3A7-NOG). The
new Center will evaluate the new strains for their suitability
for human infections, immunity, drug interactions, and vac-
cine studies.
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